Cart
sales@molnova.com
DMH-25
CAS No. 1685280-21-0
DMH-25( —— )
Catalog No. M22216 CAS No. 1685280-21-0
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 268 | Get Quote |
|
| 10MG | 408 | Get Quote |
|
| 25MG | 672 | Get Quote |
|
| 50MG | 945 | Get Quote |
|
| 100MG | 1278 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDMH-25
-
NoteResearch use only, not for human use.
-
Brief DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
-
DescriptionDMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1685280-21-0
-
Formula Weight489.94
-
Molecular FormulaC15H8Br3NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.amélie, fouqué, Delalande O , Jean M , et al. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells[J]. Journal of Medicinal Chemistry, 2015:6559-73.
molnova catalog
related products
-
AZD 3147
AZD 3147 is an inhibitor of mTORC with IC50s of 40.7 and 5.75 nM for mTORC1 and mTORC2. AZD 3147 shows IC50s of 912, 5495, 9333, and 6310 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively.
-
Deforolimus
A potent, selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line.
-
CC-223
A potent, selective, and orally bioavailable inhibitor of mTOR kinase with IC50 of 16 nM.
